---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-008020"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2023-01-30T23:59:59+00:00"
generated_at: "2026-06-20T06:43:34.975120+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics appoints John Hamill as CFO, replacing Scott Coiante

## Summary
- John Hamill appointed CFO effective Jan 30, 2023; succeeds Scott Coiante who remains through March 31.
- Hamill brings over 30 years finance experience; previously CFO at Windtree Therapeutics, Trevena, NephroGenex.
- Compensation: $420k base salary, 40% target bonus, $50k sign-on bonus (payable March 2024).
- Equity grant: options for 539,758 shares (4-year vest) and RSUs for 269,879 shares (3-year vest).
- Coiante receives 12 months base salary and health benefits under separation agreement.

## SEC filing metadata
- accession: 0001104659-23-008020
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2023-01-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000110465923008020/0001104659-23-008020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000110465923008020/tm234708d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-008020
- JSON: https://secwatch.observer/filing/0001104659-23-008020.json
- Plain text: https://secwatch.observer/filing/0001104659-23-008020.txt

## Key facts
- Executive change
  Scott Coiante departed as Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer at Aprea Therapeutics, Inc..
  - Action: stepped down
  - Role: Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer
  source text: Mr. Hamill will replace Scott Coiante, who will step down from his role as Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective as of the Transition Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000110465923008020/0001104659-23-008020-index.htm
- Executive change
  John Hamill was appointed as Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer at Aprea Therapeutics, Inc..
  - Action: appointed
  - Role: Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer
  source text: Effective January 30, 2023 (the “Transition Date”), John Hamill became Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer of Aprea Therapeutics, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000110465923008020/0001104659-23-008020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.